Browse studies

Find your next paid study

26,914 recruiting studies available now

A Prospective Registry of Vaginal Photobiomodulation for Chronic Pelvic Pain: The VOICE Registry.

The VOICE Registry is a multicenter, prospective, observational registry designed to collect real-world data on the clinical use of SoLá Pelvic Therapy® (SPT) …

Chronic Pelvic Pain

Estimated

~$10 – $1,125

SoLa Pelvic TherapyNCT07799857

Observational

Multicenter Pivotal Study of the Velocity™ Percutaneous Arterio-Venous Fistula System

This study will evaluate the Velocity Percutaneous Arteriovenous Fistula (pAVF) System, a new minimally invasive method for creating dialysis access. People wi…

Chronic Kidney DiseaseHemodialysis AccessArteriovenous Fistula+1 more

Estimated

~$10 – $7,500

Venova MedicalNCT07153939

Phase 3

A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury - A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Trial (RESTORE)

The goal of this clinical trial is to learn if NVG-291 can improve function in adults with chronic cervical motor-incomplete spinal cord injury. It will also l…

Chronic Spinal Cord Injury

Estimated

~$10 – $8,750

NervGen PharmaNCT07799532

Observational

The Vanguard Study: Testing a New Way to Screen for Cancer

The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized control…

Bladder CarcinomaBreast CarcinomaColorectal Carcinoma+8 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06995898

Observational

Remote Dielectric Sensing Technology Guided Diuresis in Hospitalized Patients With Acute Decompensated Heart Failure

This study evaluates the use of a wearable vest capable of non-invasively measuring lung fluid content in hospitalized patients with heart failure

Heart Failure; With Decompensation

Estimated

~$10 – $5,625

University of California, San FranciscoNCT03586336

Phase 1

An Open-label, Phase 1, Dose-Finding Study to Characterize the Safety, Tolerability, and Pharmacokinetics of a Long-Acting Injectable KarXT Formulation in Participants With Schizophrenia

A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia

Schizophrenia

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT07061288

Phase 2

Sensory Phenotyping to Enhance Neuropathic Pain Drug Development (SPENDD): A Randomized, Double-blinded Cross-over Clinical Trial Aimed at Investigating Whether Bedside Quantitative Sensory Testing Can Predict Response to Analgesics.

The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predic…

Painful Peripheral NeuropathyDiabetic Peripheral Neuropathic Pain (DPN)Chemotherapy Induced Peripheral Neuropathy (CIPN)+1 more

Estimated

~$10 – $6,250

University of RochesterNCT06614322

A Multi-Center Registry Study to Assess the Safety and Effectiveness of Photobiomodulation (PBM) in Participants With Dry Age-Related Macular Degeneration (AMD) (GLOBALIGHT)

The purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM…

Dry Age-related Macular Degeneration

Estimated

~$10 – $1,050

LumiThera, Inc.NCT06351605

Phase 2

A Randomized Phase II Trial of ASTX727 and Venetoclax Compared With ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults With IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy

This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatme…

Acute Myeloid Leukemia

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06672146

Phase 3

Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas

This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed…

Astrocytoma, IDH-Mutant, Grade 3

Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT07215910

Phase 3

ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatm…

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Early Stage HER2+ Breast Cancer

Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT06876714

Phase 1

A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator's Choice of Adjuvant Chemotherapy in Participants With Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Some people with pancreatic ductal cancer (PDAC) have a protein called Claudin 18.2 (CLDN18.2) in their tumor. ASP2138 is thought to work by binding to CLDN18.…

Pancreatic Ductal Adenocarcinoma

Estimated

~$10 – $8,750

Astellas Pharma Global Development, Inc.NCT07024615